Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibody Technology Fuels Deals For Arana In Australia, Japan, Korea: PharmAsia News Spotlight

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Sydney-based biotech Arana Therapeutics announced completion of a second collaborative project with Australian pharma partner CSL Limited, June 5

You may also be interested in...



Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary

PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary

Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary

PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary

Cephalon Purchases Majority Stake In Australian Biotech Arana, Clearing Way For Full-scale Acquisition

PERTH, Australia - Through ongoing buying of shares in the target company, Cephalon International Holdings has achieved a controlling 50 percent-plus interest in Australian biotech Arana. Cephalon's offer to acquire Arana is now "free from all outstanding conditions," Cephalon announced May 20

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel